1) second-line chemotherapy
二线化疗
1.
Second-line chemotherapy in sensitive or refractory small cell lung cancer after primary treatment with platinum and etoposide;
足叶乙甙联合铂类一线化疗后复发的小细胞肺癌二线化疗的临床研究
2.
Objective:To investigate the efficiency and toxicity of gemcitabine with cisplatin as second-line chemotherapy for patients with advanced NSCLC.
方法:对38例晚期非小细胞肺癌患者采用二线化疗,入组患者均经病理组织学证实,有可测量病灶,方案为吉西他滨1000mg/m2第1、8天,顺铂80mg/m2,分3天应用,21天为1个周期。
3.
Paclitaxel-based regimens as second-line chemotherapy for patients with advanced gastric cancer;
7%)为铂类治疗失败的患者,既往治疗方案对紫杉醇二线化疗疗效无明显影响。
2) second line chemotherapy
二线化疗
1.
Purpose:To investigate the effect of secondary cytoreductive surgery and second line chemotherapy on survival of patients with epithelial ovarian cancer who failed with platinum based chemotherapy or relapsed after remission.
5～ 36)月的卵巢癌患者接受二次肿瘤细胞减灭术及术后二线化疗。
3) second-line treatment
二线治疗
1.
Objective To evaluate the effectiveness and safety of the second-line treatment on patients with advanced non-small cell lung cancer(NSCLC).
结论多西他赛单药二线治疗晚期非小细胞肺癌疗效肯定,耐受性较好。
2.
Objective To observe the efficacy of Paclitaxel (PTX) combined with Carboplatin (CBP) and Medroxyprogesterone acetate (MPA) to reverse multi-drug resistance, or PCM regimen, in second-line treatment of advanced non-small cell lung cancer, and the influence of MPA on diet, weight and marrow of the patients.
目的观察紫杉醇(PTX)联合卡铂(CBP)加甲孕酮(MPA)作为耐药调变剂即PCM方案二线治疗晚期非小细胞肺癌(NSCLC)的疗效及甲孕酮对患者饮食、体重及骨髓的影响。
4) second-line therapy
二线治疗
1.
Development of second-line therapy for advanced pancreatic cancer
晚期胰腺癌二线治疗的研究进展
2.
Objective To evaluate the efficacy and toxicity of irinotecan combined with nedaplatin in second-line therapy of small-cell lung cancer.
目的观察伊立替康联合奈达铂二线治疗小细胞肺癌的疗效及毒副反应。
5) Second-line Chemotherapy of Ovarian Cancer
卵巢癌的二线化疗
补充资料：二线
①战争中的第二道防线。②比喻不负有直接领导责任的地位：退居～。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条